Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma

BACKGROUND: Despite advances in therapeutics, outcomes for hepatocellular carcinoma (HCC) remain poor and there is an urgent need for efficacious systemic therapy. Unfortunately, drugs that are successful in preclinical studies often fail in the clinical setting, and we hypothesize that this is due...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Weining, Iyer, N. Gopalakrishna, Tay, Hsien Ts’ung, Wu, Yonghui, Lim, Tony K. H., Zheng, Lin, Song, In Chin, Kwoh, Chee Keong, Huynh, Hung, Tan, Patrick O. B., Chow, Pierce K. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628260/
https://www.ncbi.nlm.nih.gov/pubmed/26520397
http://dx.doi.org/10.1186/s12885-015-1814-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628260/
https://www.ncbi.nlm.nih.gov/pubmed/26520397
http://dx.doi.org/10.1186/s12885-015-1814-8

Ejemplares similares